| 0.1201 -0.005 (-4.23%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.93  |
1-year : | 3.06 |
| Resists | First : | 1.66 |
Second : | 2.62 |
| Pivot price | 0.64 |
|||
| Supports | First : | 0.1 |
Second : | 0.08 |
| MAs | MA(5) : | 0.16 |
MA(20) : | 0.75 |
| MA(100) : | 4.28 |
MA(250) : | 7.54 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 0.4 |
D(3) : | 0.4 |
| RSI | RSI(14): 29 |
|||
| 52-week | High : | 18 | Low : | 0.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTPI ] has closed above bottom band by 25.4%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.21 - 0.21 | 0.21 - 0.21 |
| Low: | 0.1 - 0.1 | 0.1 - 0.1 |
| Close: | 0.12 - 0.12 | 0.12 - 0.12 |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Tue, 06 May 2025
Petros Pharmaceuticals (PTPI) Boosts AI Platform with Advanced Features | PTPI Stock News - GuruFocus
Tue, 06 May 2025
Petros Pharma Upgrades AI Platform Following Trump Order to Expand OTC Drug Access - Stock Titan
Thu, 01 May 2025
Petros Pharmaceuticals (PTPI) Aims to Transform with Innovative Healthcare Platform | PTPI Stock News - GuruFocus
Tue, 29 Apr 2025
Petros Pharmaceuticals stock plunges to 52-week low of $0.04 - Investing.com
Tue, 29 Apr 2025
Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan
Mon, 31 Mar 2025
Petros Pharmaceuticals Inc. (PTPI) reports earnings - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 4.8 (%) |
| Shares Short | 120 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -83.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -17.73 |
| Profit Margin | -280.2 % |
| Operating Margin | -240.9 % |
| Return on Assets (ttm) | -29 % |
| Return on Equity (ttm) | -571.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.82 |
| Sales Per Share | 2.38 |
| EBITDA (p.s.) | -3.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0.05 |
| Price to Cash Flow | -0.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|